The objective of pharmaceutical cocrystallization is to create crystalline analogues that have vastly different properties, such as solubility, melting point, stability, and bioavailability from that observed in the pure active pharmaceutical ingredients (APIs). Amoxapine is a benzoxazepine derivative and exhibits antidepressant properties. Amoxapine has very low solubility in water, so it was cocrystallized with natural acids in a 1:1 ratio in appropriate solvents by the solvent-drop grinding method. Single crystals of cocrystals were grown by the solvent evaporation method in water, ethanol, and methanol. Crystal structures of API salts were determined by single-crystal X-ray diffraction. Salts were characterized by Fourier transform infr...
Poor aqueous solubility and low oral bioavailability of an active pharmaceutical ingredient are the ...
Cocrystallization is a promising approach to alter physicochemical properties of active pharmaceutic...
Improving the dissolution and pharmacokinetics of the poorly soluble active pharmaceutical ingredien...
The objective of pharmaceutical cocrystallization is to create crystalline analogues that have vastl...
The cocrystal production and properties are intricate in different ways. It exhibits properties corr...
Solubility enhancement of poorly-soluble active pharmaceutical ingredients (APIs) remains a scientif...
Abstract The selection of the crystalline phases in a form of molecular cocrystals has become scient...
Approximately 40% of newly synthesized drugs are not able to enter market due to biopharmaceutical i...
ABSTRACT: Co-crystals consists of API and a stoichiometric amount of a pharmaceutically acceptable c...
Cocrystallisation and salt formation is a widely studied method of optimising the action of Active...
Enhancing the physicochemical properties of solid-state materials through crystal engineering enable...
Crystal form (cocrystals, polymorphs, salts, hydrates and solvates) assortment remains a scientific ...
Cocrystals can be used as an alternative approach based on crystal engineering to enhance specific p...
The selection of the crystalline phases in a form of molecular co-crystals has become scientific ch...
Magister Pharmaceuticae - MPharmMany active pharmaceutical ingredients (APIs) have poor physicochemi...
Poor aqueous solubility and low oral bioavailability of an active pharmaceutical ingredient are the ...
Cocrystallization is a promising approach to alter physicochemical properties of active pharmaceutic...
Improving the dissolution and pharmacokinetics of the poorly soluble active pharmaceutical ingredien...
The objective of pharmaceutical cocrystallization is to create crystalline analogues that have vastl...
The cocrystal production and properties are intricate in different ways. It exhibits properties corr...
Solubility enhancement of poorly-soluble active pharmaceutical ingredients (APIs) remains a scientif...
Abstract The selection of the crystalline phases in a form of molecular cocrystals has become scient...
Approximately 40% of newly synthesized drugs are not able to enter market due to biopharmaceutical i...
ABSTRACT: Co-crystals consists of API and a stoichiometric amount of a pharmaceutically acceptable c...
Cocrystallisation and salt formation is a widely studied method of optimising the action of Active...
Enhancing the physicochemical properties of solid-state materials through crystal engineering enable...
Crystal form (cocrystals, polymorphs, salts, hydrates and solvates) assortment remains a scientific ...
Cocrystals can be used as an alternative approach based on crystal engineering to enhance specific p...
The selection of the crystalline phases in a form of molecular co-crystals has become scientific ch...
Magister Pharmaceuticae - MPharmMany active pharmaceutical ingredients (APIs) have poor physicochemi...
Poor aqueous solubility and low oral bioavailability of an active pharmaceutical ingredient are the ...
Cocrystallization is a promising approach to alter physicochemical properties of active pharmaceutic...
Improving the dissolution and pharmacokinetics of the poorly soluble active pharmaceutical ingredien...